Biogen (MEX:BIIB) Capex-to-Operating-Income

: 0.14 (As of Mar. 2023)

View and export this data going back to 2013. Start your Free Trial

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Biogen's Capital Expenditure for the three months ended in Mar. 2023 was MXN-1,290.59 Mil. Its Operating Income for the three months ended in Mar. 2023 was MXN9,324.33 Mil.

Hence, Biogen's Capex-to-Operating-Income for the three months ended in Mar. 2023 was 0.14.

Biogen Capex-to-Operating-Income Historical Data

The historical data trend for Biogen's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Capex-to-Operating-Income

0.15

0.10

0.12

0.11

0.08

Biogen Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Capex-to-Operating-Income																0.09	0.04	0.07	0.17	0.14

Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

Biogen Capex-to-Operating-Income Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Biogen's Capex-to-Operating-Income falls in comparison to its industry or sector. The grey bar indicates the Capex-to-Operating-Income's extreme value range as defined by GuruFocus.

Biogen Capex-to-Operating-Income Calculation

Biogen's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-4741.427)	/	56575.442
	=	0.08

Biogen's Capex-to-Operating-Income for the quarter that ended in Mar. 2023 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-1290.59)	/	9324.332
	=	0.14

Biogen (MEX:BIIB) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

Biogen Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Biogen's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen (MEX:BIIB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (MEX:BIIB) » Definitions » Capex-to-Operating-Income

Comparable Companies

Traded in Other Exchanges

BIIB:USA IDP:Germany BIIB34:Brazil BIIB:Austria BIIB:Argentina

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

http://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.